Biologics are a vital part of the care pathway for several major chronic conditions, notably cancer and autoimmune diseases, and the expiry of patents and exclusivity periods for biologics has permitted the development of biosimilars. The introduction of biosimilars has provided patients with improved access to important, life changing therapeutics.
Over time, confidence in the use of biosimilars is increasing; however, they remain a relatively novel class of treatment, and are associated with complex production and regulation processes that may not be well-understood by all.
The aim of ASK is to increase prescriber confidence in knowledge and clinical use of oncology biosimilars via education on the foundations for protein synthesis, the specifics of biosimilar manufacture, the stringency of regulatory requirements and the application of biologics in clinical practice.
By emphasising focus around Asking the questions that exist around oncology biosimilars, developing the Skills around data and evidence interpretation, extrapolation, and evaluation, and finally sharing the Knowledge created with peers, and within their institution’s multidisciplinary team and patients.
Our program is designed for members of the oncology multi-disciplinary team (MDT) involved in treating patients with cancer, including hospital-based pharmacists, nurses and oncologists.
Why join?
- Free-to-access digital resources to continue your education
- Interact with our expert faculty and have your questions answered
- Stay updated on the latest developments and best practice for the use of biosimilars in the treatment of solid tumours
